ACW Appendix 4E and 2023 Annual Report
Filed with ASX · · 78 pages · English
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- ACW secures further $0.5m rights issue shortfall commitment
- ACW secures shortfall commitments of $4.56m for rights issue
- Entitlement Offer Prospectus
- Actinogen announces $10 million rights offer
- Quarterly Activity Report & Appendix 4C
Later from Actinogen Medical
- Actinogen FY2023 results, following the science
- Actinogen closes successful $10 million rights issue offer
- Actinogen enhances XanaMIA Phase 2b Alzheimers trial
- Actinogen September quarterly activity report & Appendix 4C
- Actinogen receives $4.8 million R&D tax incentive rebate
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical